Epidiolex maker GW Pharma reports record quarterly revenue of $137 million
United Kingdom-based GW Pharmaceuticals posted higher revenue in the quarter ended Sept. 30, largely driven by U.S. sales of its cannabidiol medicine Epidiolex.
United Kingdom-based GW Pharmaceuticals posted higher revenue in the quarter ended Sept. 30, largely driven by U.S. sales of its cannabidiol medicine Epidiolex.
The Italian Ministry of Health declined to take action under a decree that would have added certain CBD preparations into the table of medicines in its narcotics law, according to a recent notice in the country’s Official Gazette.
The first finished, registered cannabis medicine became available to patients in Peruvian pharmacies this week, Marijuana Business Daily has learned.
Denmark’s medical cannabis pilot program notched another positive quarter, but the number of unique consumers remains well below the trial’s peak of a year ago.
Companies operating bonded warehouses in Uruguay are now able to provide international logistics services for the cannabis industry, according to a recently approved decree.